Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life studyRoberta D’Ambrosio, S. Fagiuoli, Massimo Zuin et al.|Digestive and Liver Disease|2019Cited by 17
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort StudyLuca Valenti, I. Carderi, Marie Graciella Pigozzi et al.|Hepatology Communications|2021Cited by 14
Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from ItalyL. Pasulo, Giuliana Cologni, M. Gambato et al.|Digestive and Liver Disease|2019Cited by 1
THU-141-Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patientsMartina Gambato, Marie Graciella Pigozzi, Angiola Spinetti et al.|Journal of Hepatology|2019Cited by 1
THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from ItalyL. Pasulo, Antonio Albanese, Martina Gambato et al.|Journal of Hepatology|2019Cited by 1